Skip to content

Safety and efficacy of Mazor spinal robot-assisted unilateral modified approach percutaneous vertebroplasty (PVP) for treatment of lumbar Kummell's disease

Safety and efficacy of Mazor spinal robot-assisted unilateral modified approach percutaneous vertebroplasty (PVP) for treatment of lumbar Kummell's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058659
Enrollment
Unknown
Registered
2022-04-13
Start date
2023-07-25
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Kummell disease

Interventions

Experiment group:Mazor spinal robot-assisted unilateral modified approach percutaneous vertebroplasty
Control group:Bilateral percutaneous vertebroplasty with free hand

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of osteoporosis; 2. Aged >= 60 years, with obvious symptoms of low back pain and limited activity; 3. lumbar compression fracture of a single vertebral body; 4. Imaging suggested that there were depressions or transverse light transmittance changes in the vertebral body, and characteristic vacuum fissure sign (IVC) appeared in the vertebral body; 5. Imaging suggested stage I and II Kummell's disease without neurological symptoms of lower limbs; 6. Imaging showed that the posterior wall of the vertebral body was intact, and no fracture block invaded the spinal canal; 7. No fractures in other parts or dysfunction of important organs, and can tolerate surgery.

Exclusion criteria

Exclusion criteria: 1. Kummell's disease with neurological symptoms; 2. Preoperative X-ray examination showed that the vertebral compression degree of fracture was > 75%; 3. Severe deformity of local kyphosis (Cobb's Angle >= 40 degree); 4. Patients suspected of having primary or metastatic vertebral lesions, multiple myeloma and metabolic bone disease; 5. Chronic thoracolumbar and back pain caused by spinal degenerative diseases; 6. Vertebral fractures in other parts occurred during follow-up; 7. Patients with severe cardiopulmonary insufficiency and severe coagulation disorders have a history of drug abuse or are taking anticoagulants orally; 8. Unconscious or incapacitated persons; 9. MRI contraindications (cardio-cerebrovascular stent implantation history, pacemaker, biological stimulator, etc.); 10. Uncontrolled severe infection or high fever; 11. allergic to bone cement; 12. Vertebral fractures in other parts occurred during follow-up; 13. Previous vertebral augmentation and other spinal operations.

Design outcomes

Primary

MeasureTime frame
Cobb angle;

Secondary

MeasureTime frame
Vital signs (body temperature, pulse, respiration, blood pressure) and body weight;Bone cement leakage rate;Number of intraoperative fluoroscopy;Operation time;Blood loss;Blood RT;urine RT;Microscopic examination of urine sediment;Liver function;renal function;Blood coagulation function;Electrolyte;Inflammatory indicators;Serological indicators of infectious diseases;Serum tumor markers;ECG;cardiac ultrasonic;Vertebral height value;Wedge Angle of vertebral body;ODI (Oswestry disability index) score for quality of life;VAS score of low back pain;hospital stays;

Countries

China

Contacts

Public ContactGuo Song

Shanghai General Hospital

guosongtj@163.com+86 178 2188 0206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026